Central tolerance in the thymus is the primary mechanism for deleting autoreactive T cells. Despite this, escape of self-reactive T lymphocytes into the periphery reveals the threat of autoimmunity. To compensate for its imperfection, the thymus also produces a naturally occurring subset of Foxp3+ CD4+ CD25+ regulatory T cells with suppressive function, capable of controlling autoreactive cells. Foxp3 (forkhead box P3), the lineage-specific marker for this subset of cells, is crucial to their thymic development and peripheral function, and yet the transcriptional program driven by Foxp3 was until now largely undefined. Emerging evidence has provided insight into its role: from the ability of Foxp3 to cooperate with other transcription factors such as NFAT, to the genome-wide characterization of target genes directly bound and regulated by Foxp3. Here we discuss the discovery of naturally occurring regulatory T cells -their phenotype, development, maintenance, and function -largely as they are defined by the lineage-specific marker, Foxp3.
T-cell receptor (TCR) rearrangement, tolerance, and autoimmunity
The primary role of the immune response is to protect the body from foreign threats. This requires the immune system to recognize a countless number of pathogens and retain the ability to differentiate between 'self' and 'non-self' [1] . The breadth of this response is attributed to the genetic diversity of BCRs and TCRs which provides an extensive repertoire of immune effector cells. In the case of T lymphocytes, immature T cells in the thymus contain multiple TCR α and β chain genes, each composed of multiple gene segments. V(D)J recombination determines which TCR α and β genes are combined, during which the respective segments of each gene are pieced together by the RAG recombinase to provide an intact TCR [2] . The critical role of the thymus, however, is not in generating an extensive repertoire of TCRs, but in deleting those that are autoreactive. Thus, the specificity of the immune response for 'non-self' depends on central tolerance, whereby over 95% of the immature T cells generated in the thymus undergo negative selection to rid the body of autoreactive cells [3] .
Once the pre-T cell is expressing an intact receptor, it scans the thymus for cognate antigen presented in self-MHC molecules. The TCR is restricted to interact with MHC I or MHC II, thus dedicating the T cell to become either CD8+ or CD4+, respectively [4] . With help from the thymic transcription factor AIRE (autoimmune regulator), thymic epithelial cells ectopically express low levels of selfantigens from organs throughout the body [5] . Most, but not all, peripheral self-antigens are present in the thymus. If the TCR of an immature T cell binds self-antigen and self-MHC with low affinity, it receives a signal for maturation and undergoes 'positive selection' [6] . These T cells will go on to recognize foreign antigens in self-MHC when they reach the periphery as mature CD4+ and CD8+ T cells. Immature T cells that recognize self-antigens in self-MHC with high affinity receive a stimulus that is too overwhelm-905 npg ing for the cell, inducing death. This is the process of clonal deletion or 'negative selection' of autoreactive cells. If the TCR interaction is somewhere in between the endpoints of positive and negative selection, the T cell reacts with the self-antigen but escapes negative selection. Instead of being deleted, these cells display an anergic phenotype in the periphery, exhibiting decreased proliferation and cytokine production following TCR engagement. Finally, because not all self-antigen genes are activated by AIRE in the thymus, some immature autoreactive T cells never engage with self-antigens. These cells avoid deletion and anergy, migrating to peripheral lymphoid organs as naïve 'ignorant' cells [7] . In the periphery these T cells are autoreactive and have the potential to cause autoimmunity if they become activated or are not properly suppressed.
Autoimmunity is the failure of the immune system to maintain tolerance against 'self'. Autoreactive T cells in the periphery recognize self-antigens as foreign and begin to attack the bodies' own tissue. In multiple sclerosis (MS), for example, the body attacks oligodendrocytes composing the myelin sheath which insulates neuronal axons. This inflammatory demyelinating disease interrupts electrical signaling and nerve impulses throughout the brain and spinal cord [8] . Experimental autoimmune encephalomyelitis (EAE), an animal model for MS, also presents as a demyelinating autoimmune disease [7] . In susceptible animals, EAE is induced following injection of a myelin antigen such as myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), or proteolipid protein (PLP). EAE as a model of MS is one of many important tools essential to the study of the pathophysiology and immunology underlying autoimmune diseases.
The role of self-antigen specific CD4+ T cells in generating autoimmunity
In the late 1980s and early 1990s, investigators were addressing the causative factors of autoimmunity: whether the primary auto-reactive T cells were CD8+ or CD4+, whether pathogenesis required multiple factors working at once, and what controlled the activation of these cells. The idea that multiple types of T cells were simultaneously required for the development of autoimmunity was refuted by the finding that MBP-specific T-cell clones could transfer EAE to nude mice [9] . Studies in CD8-/-mice as well as those with anti-CD8 antibodies demonstrated that EAE develops at equal rates in the presence or absence of CD8 [10, 11] . Thus, CD8+ T cells are not essential for the pathogenesis of EAE. In 1994, Lafaille et al. showed that EAE could occur in the absence of B cells and antibodies as well [12] . Therefore, autoimmune pathogenesis of EAE may be attributed to self-reactive CD4+ T cells alone. A series of observations made around this time support this theory: (1) self-antigen-specific CD4+ T cells and MHC class II presenting antigen-presenting cells (APCs) are present in inflamed tissues in MS patients [13] ; (2) the disease is associated with certain MHC II alleles, suggesting that MHC II-restricted CD4+ T cells play a role in pathogenesis [14] ; and (3) CD4+ T cells from healthy donors or patients can respond to self-Ag from the affected tissue in vitro [15] . Thus, in the absence of CD8+ T cells, CD4+ T cells do exhibit autoimmune potential.
Following antigenic stimulation, naïve CD4+ T cells can differentiate into several different functional subtypes -Th1, Th2, Th17, and Treg -depending upon the microenvironmental cytokine milieu at the time of their differentiation, and the expression of lineage-specific transcription factors (Figure 1 ). Each subset is characterized by distinct cytokine production and effector function [16] [17] [18] . Before the discovery of the Th17 lineage, pro-inflammatory, IFN-γ-producing, Th1-type CD4+ helper T cells were thought to play the major role in pathogenesis of autoimmune diseases such as multiple sclerosis or EAE, diabetes and rheumatoid arthritis. Mice that tolerate MBP and do not develop EAE demonstrate a decreased Th1 response to MBP antigen [19] . On the other hand, EAE inducing MBP-specific T cells secrete Th1 type cytokines, and induce disease in naïve mice following adoptive transfer [20] . In addition, mice lacking Th1 transcription factors (T-bet and STAT-4) are resistant to the development of EAE [21, 22] . More recent evidence, however, suggests that Th17 cells are the primary contributors, acting as even more potent pro-inflammatory mediators [23, 24] . Autoimmunity still occurs in IFN-γ or IFN-γ-receptor deficient mice, which can be prevented by neutralization of IL-17 [25] [26] [27] . IL-17 is expressed in the target tissues of patients with numerous autoimmune diseases, and neutralization of this cytokine prevents the development of EAE [28, 29] . It is not yet determined whether the roles of Th1 and Th17 cells in autoimmune pathogenesis are mutually exclusive. The observation that IL-17 expression is present during acute EAE, while IFN-γ increases and persists for a longer period in the CNS of these mice, suggests that perhaps both subsets cooperate to induce tissue-specific autoimmunity [30] .
Regulating autoimmunity: the presence of a suppressor cell
As mentioned above, self-reactive CD4+ T cells can avoid central tolerance mechanisms in the thymus and escape to the periphery. In fact, these cells are present in the periphery of healthy animals, but rarely cause autoimmune diseases. Generally, they remain innocuous until activated. For instance, MBP-specific T cells present in Immunological tolerance with Foxp3 906 npg healthy humans and mice remain at bay until activated by immunization with MBP [15, 31] . In TCR transgenic mice, where the frequency of MBP-specific T cells is increased, EAE can develop spontaneously [7] . In other words, if the frequency of auto-reactive T cells is high, immunization with antigen and adjuvant is not needed to activate those cells. This indicates that when a higher percentage of the CD4+ T-cell population is self-antigen-specific, the chances of auto-reactive T-cell activation are dramatically increased [12] . Overall, activation of these cells depends upon the number of self-reactive T cells, the amount and accessibility of self-antigen, the inflammatory cytokine environment at the time of antigen encounter, and the absence of suppressor cells to counteract the response.
Evidence to support that autoreactive CD4+ T cells can be actively suppressed was demonstrated in the early 1990s. In 1994, Lafaille et al. crossed MHC II (H-2 A u ) restricted, MBP-specific TCR transgenic mice with RAG-1-deficient mice [12] . RAG-1-deficient mice are incapable of forming endogenous BCR and TCR, and are thus B and T lymphocyte deficient. The cross of a TCR transgenic (T/R+) to a RAG-1 -/-mouse resulted in progeny (T/R-) with T cells expressing only the MBP-specific TCR and no other lymphocytes. In their study, Lafaille et al. showed that T/R-mice developed EAE 100% of the time when no other lymphocytes are present, while EAE only occurred 14% of the time in T/R+ mice with an otherwise normal immune system [12] . Thus, in the absence of other nontransgenic lymphocytes, MBP-specific CD4+ T cells induce spontaneous autoimmunity 100% of the time. However, the presence of the non-transgenic lymphocytes appears to have a protective effect that suppresses the potential of auto-reactive cells to cause spontaneous EAE. In another study, Kumar and Sercarz generated specific CD4+ T-cell clones from the lymph nodes of mice that had recovered from MBP-induced EAE, and showed that these CD4+ T-cell clones protected mice from MBP-induced EAE in adoptive transfer experiments [32] . In addition, Fowell and Mason showed that, in rats, normal non-autoimmune animals develop diabetes following a thymectomy, which renders them lymphopenic. Autoimmunity was completely prevented by replenishing syngeneic T cells of a particular CD4+ subset shortly after treatment [33] . In total, these results suggest that a special subset of CD4+ T lympho- 
Identifying the suppressor cell: CD4+ CD25+ Foxp3+ Tregs
At this time, the role of a suppressive T-cell population of thymic origin was not a novel concept. Work from the late 1960s and early 1970s led by Gershon and Kondo introduced the concept of endogenous suppressor T cells with immunoregulatory properties [34] . This theory was largely refuted by the scientific community after a failure to clone the cell, and the inability to identify a lineage-specific marker. In 1994, after a lull in the field, CD4+ T-cell clones that were capable of suppressing MBP or PLP-induced EAE were reported [35] . As the theory of a suppressive factor was reignited, the history of the field stressed the importance of identifying unique markers which could be used to isolate the specific population of naturally arising 'regulatory' cells. Once identified, it could be determined whether removal of that subpopulation would contribute to a break in self-tolerance leading to autoimmunity, and whether its reconstitution could prevent the onset of disease [36] .
Regulatory T-cell surface markers
Initial studies have shown that adoptive transfer of CD4+ T-cell populations depleted of CD5 high or CD45RC low CD4+ T cells to T-cell-deficient mice resulted in spontaneous autoimmune disease [37] . The use of CD45RC low as a marker appeared to include the regulatory population; however, this marker is not unique to these cells, as its expression is downregulated on all CD4+ T cells after they have encountered antigen. An attempt to identify the specific CD4+ T cell type involved in suppression focused on the surface marker CD25, the IL-2 receptor α-chain. The CD25+ cells belong to the CD5 high , CD45RC low population, and only 5-10% of peripheral CD4+ T cells (and less than 1% of CD8+ T cells) express CD25 [38] . Transfer of splenic cell suspensions depleted of CD4+ CD25+ T cells into Tcell-deficient recipients resulted in severe autoimmunity. Reconstitution of CD4+ CD25+ T cells within a short time after transfer prevented development of the disease [38] . Therefore, even though the normal immune system contains self-reactive CD4+ CD25-T cells capable of inducing autoimmunity, their activation is suppressed by a population of regulatory CD4+ CD25+ T cells. Elimination of this population can break self-tolerance, leading to the onset of autoimmune disease.
The majority of CD4+ CD25+ Tregs constitutively express low levels of CTLA-4, a surface marker on T cells which outcompetes CD28 for binding to B7 (CD80/86) on APCs. The binding of CTLA-4 to B7 sends inhibitory signals to the T cell. CTLA-4 is also present on effector T cells, where it becomes active following costimulation and T-cell activation, as a mechanism to control lymphoproliferation. It has been suggested that this constitutively expressed marker plays a functional role in CD4+ CD25+ Treg-mediated suppression [39] . Another surface marker on CD4+ CD25+ regulatory T cells is the glucocorticoidinduced TNF-receptor-related gene GITR. Constitutive, high-level expression of this molecule is considered a unique marker of Tregs as GITR is not present on naïve, conventional CD4+ T cells and is only upregulated on responder cells following TCR engagement [40] . The interaction of GITR on CD4+ CD25+ Tregs with its ligand (GITRL) on the surface of APCs abrogates suppression resulting in autoimmunity [41] . Evidence suggests that, in addition to attenuating Treg activity, engagement of GITR may also co-stimulate effector T cells, making them less susceptible to suppression [42] . The role of GITR-GITRL interactions in regulatory activity was recently reviewed by Shevach and Stephens [43] .
The master regulator: Foxp3
While these cell surface markers, predominantly CD25, are useful for characterizing regulatory T cells in mice and humans, they are not expressed exclusively on Tregs. Expression of CD25 is upregulated upon activation of all T cells [44] . Therefore, the use of CD25 to differentiate regulatory T-cell populations depends upon a relative standard. CD4+ CD25+ Tregs are CD4 low CD25 high . They express CD25 constitutively and upon TCR stimulation the expression of this marker is higher and more persistent than on non-regulatory CD4+ T-cell populations [44, 45] . The latter population of T cells, on the other hand, is CD25-prior to activation, and loses CD25 expression following stimulation. Due to its slightly subjective nature, CD25 is not a perfect marker for Treg identification. As such, discovery of a unique, lineage-specific marker for this subpopulation of cells was a substantial accomplishment for the field.
Identification of a unique Treg marker surfaced in an animal model of autoimmunity. Scurfy mice present lymphoproliferation, lymphocytic infiltration and multi-organ autoimmune disease [46] . Upon analysis, the disease was shown to be mediated by CD4+ T cells [47, 48] . In 2001, the mutation responsible for the scurfy phenotype in mice was identified in the gene encoding Foxp3 [49] . Mutation within the same gene in humans was determined to be the cause of the fatal autoimmune disorder IPEX [50] . Foxp3, named for its winged helix-forkhead DNA-binding domain, functions
Immunological tolerance with Foxp3 908 npg as a transcription factor. Full-length Foxp3 holds very high sequence homology across human, mouse, and rat [51] . In mice, this X-linked recessive disease appears to operate by a mechanism of dominant tolerance. Scurfy affects males, but not heterozygous females. Random X inactivation in heterozygous females results in a combination of cells with normal and defective Foxp3 [52] . There is no disease phenotype in these mice as the residual Foxp3-expressing cells dominantly control the population of self-reactive T cells. Foxp3-mutant scurfy mice are deficient in CD25+ CD4+ T cells, and the onset of autoimmunity can be prevented by expression of normal Foxp3+ CD25+ CD4+ Tregs [49, 53] . In 2003, Fontenot et al. generated conditional Foxp3-null mice using homologous recombination, by creating mice carrying a floxed Foxp3 allele which can be crossed with a Cre-deleter transgenic strain to produce males with targeted deletion in Foxp3 [45] . As seen in Foxp3-mutant scurfy mice, the Foxp3-null mice exhibit CD4+ CD25+ Treg deficiency, resulting in a lethal, lymphoproliferative, autoimmune phenotype which can be rescued by transfer of regulatory T cells [45] .
Functionally, Foxp3+ CD25+ CD4+ regulatory T cells appear anergic in vitro: they do not proliferate or secrete IL-2 in response to TCR stimulation as their effector counterparts do [44, 45] . And yet, following crosslinking of the TCR, these cells are able to inhibit proliferation and cytokine production by those effectors [51] . Expression of Foxp3 is necessary and sufficient for suppressor function of natural Tregs as Tregs from Foxp3+ mice maintain their characteristic behavior in vitro, being hyporesponsive to TCR stimulation themselves and capable of suppressing the proliferation of CD4+ CD25-effectors. In contrast, there is no suppressor activity in the CD4+ CD25+ population from Foxp3-mice [45] . In addition, retroviral transduction of CD25-T cells with Foxp3 results in the functional conversion of these cells to Tregs with suppressive properties [54] . These cells exhibit decreased IL-2 production and increased expression of characteristic Treg surface markers such as CD25, CTLA-4, and GITR [53] . CD25-cells also acquire the ability to suppress effector T-cell proliferation in vitro and prevent autoimmunity in vivo following ectopic expression of Foxp3 [45] .
Moreover, this transcription factor is unique to CD4+ CD25+ regulatory T cells. A comparison of mRNA and protein levels in CD25+ versus CD25-T cells showed that, while Foxp3 is highly expressed in CD25+ CD4+ CD8-peripheral T cells and thymocytes, it is present in low to undetectable levels in both naïve and activated CD4+ CD25-T cells, as well as in other T, B, NK, and NKT cells [45, 53, 54] . Overall, of the 15% of T cells express- npg ing Foxp3, 70-80% are also CD4+ CD25+. Notably, these cells also constitutively express GITR at high levels [55] . Taken together, the transcription factor Foxp3 is specifically expressed in the CD4+ CD25+ population of T cells, and is required for the generation of regulatory properties.
Thymic development of natural Tregs
Development of Foxp3+ CD25+ CD4+ regulatory T cells occurs in the thymus (Figure 2) . Removal of this organ by thymectomy in neonatal mice results in autoimmunity, which can be reversed by transferring peripheral CD25+ CD4+ Tregs [51] . CD25+ T cells appear to migrate to the periphery by day 3, as thymectomy at day 3, but not after, leads to autoimmunity. CD25+ cells can be isolated from the CD4+ thymocyte compartment of mice and humans and have suppressive activity in vitro and following adoptive transfer in vivo [56] [57] [58] . In addition to having the same in vitro and in vivo regulatory function as peripheral Tregs, CD25+ CD4+ CD8-thymocytes are also similarly anergic and have the same surface molecule expression patterns: CTLA-4+ and GITR+.
Role of TCR signaling
The MHC class restriction of the thymocyte TCR dictates commitment to a T-cell lineage [6] . The role of TCR signaling in the development of CD4+ CD25+ Tregs was suggested by the observation that RAG-2 deficiency eliminates CD25+ thymocytes and T cells. Thus, TCRs endogenously rearranged in the thymus are required for the development of CD25+ Tregs in these mice. Furthermore, the proportion of Tregs that develop in TCR transgenic mice is increased in mice that are bred onto a strain expressing a transgene encoding the cognate ligand, speaking to the role of TCR-ligand interaction in Treg development [59] [60] [61] . The importance of TCR cross-linking in development is also supported by the observation that relative numbers of Tregs are reduced in mice with genetic defects in targets of downstream TCR signaling [62, 63] . As discussed in the introduction, thymic development of Tregs requires an increased strength of TCR signaling somewhere above what is required for the positive selection of effector T cells, and below what will result in clonal deletion through negative selection [60] .
Following TCR ligation, unique signaling pathways must be activated to initiate the transcriptional program required for Treg lineage commitment. Recent findings indicate that the signaling requirements needed to induce Treg development are distinct from those leading to the positive selection of other thymocytes. For instance, while a mutation in the tyrosine phosphorylation site in the Y136F variant of LAT (linker of activated T cells) results in a complete lack of Foxp3+ Tregs in both the thymus and periphery, there is only a partial defect in positive selection [64] . LAT is a transmembrane adaptor protein essential for T-cell activation and thymocyte development [65] . This study has indicated the involvement of LAT signaling in inducing Foxp3 expression and CD4+ CD25+ Treg development. Activation of the NF-κB signaling pathway has also been implicated in Treg development as impairment of this pathway leads to a deficiency of Treg cells [62, 63] . Recent reports question whether this effect is an indirect result of non-regulatory T cells becoming deficient in IL-2 production, which is required for the upregulation of CD25 and the peripheral maintenance of Tregs. The signaling pathways involved in thymic Treg development are reviewed in further detail by Liston and Rudensky [66] .
It has also been suggested that Treg lineage commitment is not secured by the increased affinity of the TCR alone, but also relies on additional signals that remain poorly understood [67] . At the very least, secondary signaling events through other, antigen-independent surface molecules are likely to play a supporting role in thymic Treg development. The number of CD25+ CD4+ CD8-thymocytes and Tregs is greatly reduced in CD28-, B7 (CD80/86)-, Il2-, Il2ra-, LFA-1-, or CD40-deficient mice [68] . Absence of these accessory molecules is likely to alter the interaction of developing Tregs with stromal cells of the thymic epithelium. Engagement of CD28 on the T-cell precursor to CD80/86, for example, is important for providing costimulation to the dominant TCR-mediated signal (Figure 2 ). Tregs developed in the absence of CD28 retain their repressive function, suggesting that, while CD28 engagement may enhance or alter it, this costimulatory factor is not required for Treg development [69] .
Role of Foxp3
The signaling pathways activated following an increased affinity TCR engagement in combination with secondary signals such as CD28 costimulation drive the expression of the lineage-specific marker, Foxp3 [45] . As a transcription factor, Foxp3 could then activate genes required for the unique Treg function and simultaneously repress those involved in other developmental pathways [70, 71] (Figure 2 ). It has been suggested that Foxp3 is needed for both development and function, as disrupting the Foxp3 gene blocks the development of natural Tregs or produces dysfunctional Tregs, the result of which is hyperactivation of auto-reactive T cells leading to autoimmunity [45, 53, 54] . Bone marrow chimera models demonstrate that Foxp3-deficient bone marrow cannot generate a CD25+ Treg population [45] .
A recent paper, however, argues that, while the function of Tregs is Foxp3 dependent, development of this lineage may not entirely depend upon Foxp3 [72] . It is true that when Foxp3 is deficient, T cells lack regulatory function and mice develop autoimmunity. However, by labeling a non-functional version of Foxp3 with a GFP marker, Lin et al. have shown that pre-Tregs developing in the thymus retain certain intrinsic Treg qualities even though the Foxp3 protein they express is non-functional. Again, these cells failed to gain suppressor activity, yet they retain similar thymic development, cell surface phenotype, and a gene expression profile that is largely similar to that seen in Foxp3 expressing natural Tregs [72] .
Overall, while there is no doubt that Foxp3 is a specific marker of developing Tregs, our understanding of the exact role that Foxp3 plays in directing development and lineage commitment remains incomplete. It appears that a certain increased avidity of TCR engagement (possibly in combination with other costimulatory interactions as discussed above) triggers a characteristic regulatory T-cell developmental pathway, marked by a certain pattern of thymic development and gene expression. Normally, the predominant gene induced by this signal is Foxp3, a transcription factor that regulates the gene expression profile of Tregs. The presence of this transcription factor is required for Tregs to acquire function, while certain components of the Treg phenotype may still be retained in its absence. As it seems, Foxp3 is not the only product of TCR engagement contributing to the acquisition of the natural Treg phenotype, though it is both necessary and sufficient for the generation of regulatory function in these cells.
The expression of Foxp3 and the subsequent development of regulatory T cells are also influenced by the development of the thymic epithelium itself. Thymic stromal cells not only provide the peptide-MHC complexes to engage immature TCRs but are also the source of secondary signals involved in dictating lineage commitment. Reports indicate that the development of Foxp3+ thymocytes is linked to that of the medullary thymic epithelium (mTEC). The majority of Foxp3 expressing thymocytes are localized to the medullary region of the thymus [73] . Another example of this link lies in the role of CD28. While Treg development requires the presence of CD28 [74] , expression of the cognate ligand, B7 (CD80/86), is largely restricted to the mTEC [75] . Overall, it is believed that the additional signal required for Foxp3 expression, whether it is the expression of CD28 ligands or other cell surface molecules or cytokines, is localized to the mTEC.
Peripheral maintenance of Tregs
The expression of the IL-2R α chain (CD25) as a predominant marker of Treg function indicates that its ligand, interleukin 2 (IL-2), may be involved in the development, function, or maintenance of regulatory T cells. The necessity of IL-2 to Tregs was encouraged by the finding that IL-2-and IL-2Rα/β chain deficiencies lead to an autoimmune phenotype in mice, and a reduction in the number of CD25+ CD4+ CD8-thymocytes and peripheral Tregs [76] [77] [78] , both of which can be prevented by addition of IL-2 [79] [80] [81] . Neutralization of IL-2 with a monoclonal antibody also leads to the induction of autoimmunity in mice, a phenotype similar to that seen following Treg depletion. Foxp3+ CD25+ Tregs in the thymus and periphery are reduced in number and unable to proliferate in the absence of IL-2 [82] . Furthermore, the autoimmune phenotype in Balb/c mice following anti-IL-2 treatment can be adoptively transferred to nude mice. Co-transfer of CD25+ Tregs was able to prevent the onset of disease [82] . These results indicate that IL-2 is required for peripheral maintenance and activation of the regulatory T-cell population. Setoguchi et al. also described that activated nonregulatory T cells in the periphery, including autoreactive CD4+ cells, are the source of IL-2 [82] . Analysis of IL-2 mRNA and protein expression shows that its expression levels are high in CD4+ CD25-/ low cells and low in the CD25+ Treg population.
As one would expect, the presence of IL-2 stimulates CD25 expression, increasing the number of CD25+ Tregs [83, 84] . Conversely, an increase in Foxp3 expression within these cells is followed by a decrease in levels of IL-2 transcription as Foxp3 downregulates the IL-2 promoter [54] . Thus, while IL-2 appears to be required for the peripheral maintenance and activation of CD25+ Tregs, the expression of the Foxp3 transcription factor in these cells downregulates IL-2. A negative feedback control loop appears to be in place, in which effector T cells in the periphery secrete IL-2 to maintain and activate regulatory T cells, which downregulate their own IL-2 expression with Foxp3, and limit the expansion of those effectors. Once activated, regulatory T cells not only suppress the auto-reactive T cell population directly but also deprive them of the essential growth factor, IL-2.
It is important to remember that, while IL-2 deficiency significantly reduces the number of Foxp3+CD25+CD4+ Tregs, these cells are present in the absence of IL-2 [85] . A re-evaluation of the role of IL-2 has shown that this cytokine is dispensable for the development of Treg cells in the thymus, but essential for their peripheral maintenance [86] . In the thymus, it appears that signaling through the common γ chain (γc, CD132) rather than the IL-2Rα chain is the crucial component in the development of Tregs [87] . Thus, in the absence of IL-2, these signals can be provided by other common γ-chain family cytokines. Evidence for the partially redundant role of IL-2 in the thymus has raised questions of whether the peripheral maintenance of Tregs [88] . However, other common gamma chain cytokines, such as IL-4, IL-7, and IL-15, were also able to maintain the maximal regulatory function of Tregs [88] . This study suggests that there is a degree of redundancy in the cytokines capable of maintaining peripheral Treg function in vitro. It will be important to understand the true role of IL-2 in vivo as well, as the peripheral requirements for Treg function may manifest similar redundancies as those seen in the thymic ontogeny of these cells.
The function of Foxp3
Foxp3 as a transcription factor True to its role as a transcription factor, when Foxp3 is expressed following TCR stimulation, it localizes to the nucleus and binds DNA to modulate gene expression as a transcriptional regulator [89] . Foxp3 has been shown to repress IL-2 and IL-4 gene transcription, and upregulate the expression of CD25 and CTLA-4 [54, 89, 90] . It was noticed that many of the genes regulated by Foxp3 are also target genes for the transcription factor NFAT [90] ; NFAT upregulates IL-2, IL-4, CD25, and CTLA-4 [91] [92] [93] . NFAT includes four calcium-regulated transcription factors [92, 93] , and in T cells it forms a strong cooperative complex with AP-1 proteins to upregulate expression of genes associated with T-cell activation [91] . While NFAT: AP1 complexes play a role in T-cell activation, NFAT can also upregulate negative regulators of T cell signaling in an AP-1-independent manner, contributing to T-cell anergy [94, 95] . The assumption that Foxp3 and NFAT interact in some way was supported by the identification of forkhead binding domains adjacent to NFAT transcription factor binding sites in the promoters of several cytokine genes (including IL-2, IL-4, and TNF) [89, 96] . Several mechanisms of interaction have been suggested: (1) Foxp3 and NFAT compete for DNA binding [89] ; (2) Foxp3 sequesters NFAT, preventing it from binding DNA to activate T cells [97] ; and (3) a cooperative complex forms between NFAT and Foxp3 [90] . In 2006, Wu et al. provided convincing evidence for the latter theory, showing that Foxp3 inhibits the formation of nuclear NFAT:AP1:DNA complexes by forming an NFAT:Foxp3:DNA complex [90] (Figure 2 ). Chromatin immunoprecipitation (ChIP) experiments confirmed that both transcription factors could occupy the IL-2, CTLA-4, and CD25 promoters, and that NFAT binding at these sites was substantially increased in Foxp3-expressing cells, suggesting that Foxp3 expression stabilizes NFAT promoter binding. Structure-based mutations of Foxp3, disrupting its interaction with NFAT, were shown to decrease its ability to repress IL-2. Mutations in this interface also interfered with the ability of retrovirally transduced Foxp3 to upregulate CTLA-4 and to a lesser extent CD25, CD103 and GITR expression. These mutations go on to impair the regulatory function of Foxp3 expressing Tregs, which become incapable of preventing autoimmunity [90] . Thus, the transcriptional role of Foxp3 in developing suppressor function depends crucially on the integrity of the Foxp3: NFAT interface, suggesting that a cooperative complex is formed between NFAT, Foxp3, and DNA.
Targets of Foxp3
While it appears to regulate transcription through cooperative interaction with other transcription factors such as NFAT, the transcriptional program of Foxp3 remains largely undefined. Two recent papers have supplied more evidence for the precise function of Foxp3 by elucidating target genes of this transcription factor in a genome-wide approach [70, 71] .
Marson et al. used ChIP combined with DNA microarrays to identify genes occupied by the transcription factor Foxp3 [71] . Foxp3-CD4+ T-cell hybridomas with and without transduction of FLAG-tagged Foxp3 were used to compare the specific effect of this transcription factor on gene expression. They discovered that the promoters of 1 119 genes are direct targets of Foxp3 binding. Included in this list are promoters for IL-2, CD25, and GITR. Consensus forkhead binding motifs were located at each of these genomic loci, and neighboring sites were enriched for NFAT-binding sequence motifs, supporting the idea of cooperative complex formation between the two transcription factors. By comparing the list of genes occupied by Foxp3 to the biological pathways in which those genes are activated, it appears that Foxp3's targets are most strongly associated with the TCR signaling and activation pathway. In order to determine whether Foxp3 binding truly affects expression of these target genes, microarray expression profiling was pursued to identify genes that were differentially expressed in Foxp3+ versus Foxp3-hybridomas. In unstimulated cells, there were few differences in the gene expression profile with or without Foxp3. However, stimulated cells express a number of genes differentially, depending on the presence of this transcription factor. To be exact, they identified 125 differentially expressed genes in Foxp3+ versus Foxp3-hybridoma cells. In stimulated Foxp3+ cells, Foxp3 binding was predominantly associated with downregulation of target genes that are normally upregulated during TCR stimulation and T-cell activation. The majority of the targets regulated in the hybridoma model are similarly regulated following stimulation of primary cells ex vivo, where the overall activation status is heterogeneous. The few differences in gene expression noted may be explained by the presence of transcriptional cofactors in ex vivo cultured cells. Overall, Marson et al. determined that the targets of Foxp3 binding are largely genes involved in TCR signaling and stimulation, and, concurrent with the role of Foxp3 in Tregs, binding of this transcription factor to its target genes appears to downregulate their expression [71] . According to these findings, the main transcriptional role of Foxp3 is to suppress genes involved in T-cell activation.
A slightly different approach was taken by Zheng et al., who used ChIP in combination with a genome tiling array to identify over 700 genes which are targets for Foxp3 binding [70] . They first demonstrated that the frequency of Foxp3 binding progressively decreases with increasing distance from the transcription start site. Preferential positioning of Foxp3-binding sites in the proximity of promoters or within the first introns provided evidence for the role of Foxp3 in classical transcriptional regulation. Gene ontology analysis revealed that Foxp3 targets are again enriched for genes involved in TCR signaling. Targets identified in this study also include genes involved in cell communication and transcriptional regulation. To confirm that Foxp3 binding played a functional role, this group also looked for genes whose expression was altered in a Foxp3-dependent manner. They reported that many Foxp3-bound genes were differentially expressed in regulatory T cells relative to naïve or activated effectors. As demonstrated by Marson et al., following stimulation with PMA and ionomycin, there was an increase of Foxp3 occupancy of the IL-2 promoter in regulatory T cells, supporting their role in IL-2 repression [70, 71] . In addition, targets subjected to Foxp3-dependent modulation included genes encoding characteristic Treg surface markers, such as CD25 and CTLA-4. Other differentially expressed targets of Foxp3 include a number of transcription factor-encoding genes. Interestingly however, 35% of Foxp3-bound genes were upregulated in Treg cells in the thymus and 6% in the periphery, while the proportion of those genes being downregulated was smaller in both locations. This finding challenges the accepted role of Foxp3 as a predominant repressor. Zheng et al. also analyzed Foxp3 binding sites for the presence of histone modifications to determine whether they play a mechanistic role in Foxp3-mediated gene regulation. Permissive histone modifications were highly prevalent in Foxp3-upregulated genes, but rare in those genes repressed by Foxp3. In addition, genes repressed by Foxp3 were enriched for inhibitory H3 modifications. This supports the idea that histone modifications are involved in Foxp3-mediated gene regulation [70] . Overall, Foxp3 appears to function as a transcriptional activator and repressor, which not only directly regulates expression of the characteristic Treg surface molecules and target genes involved in TCR signaling, but also indirectly mediates their development by targeting a network of transcription factors and epigenetic chromatin modifications to further control gene expression.
Mechanism of suppression
Identification of Treg-specific markers allowing for enrichment in cell culture has contributed to the development of in vitro systems to study Treg-mediated suppression, by analyzing the proliferation of non-regulatory T cells either alone or in co-culture with Tregs [98] . The ability to study these cells in vitro has been helpful in elucidating their functional characteristics, although the mechanisms of tolerance are still largely undefined. What has become apparent is that Tregs appear to operate by multiple mechanisms of suppression, ranging from indirect suppression through secretion of soluble factors such as cytokines to direct suppression through binding of cell surface molecules [99] (Figure 3 ). While suppressor function requires Tregs to be activated through their TCR, these cells display distinct functional properties in vitro versus in vivo [98] .
Membrane-associated mechanisms of suppression (contact dependent)
Suppression in vitro appears to be contact dependent as it does not occur when cells are separated by a permeable membrane [98] . It is also not affected by lack of soluble factors such as TGFβ or IL-10, as Tregs isolated from mice with deletions in these genes retain their suppressive activity in vitro [98] [99] [100] . Antibodies to TGFβ, on the other hand, do inhibit suppressor function in vivo, suggesting a contact-dependent mechanism involving surface-bound TGFβ [101] . Because Tregs constitutively express the inhibitory surface molecule CTLA-4, there has been interest in determining whether binding of this molecule to B7 (CD80/86) on APC or T cells may play a role in suppression. Indeed, treatment with monoclonal antibody against CTLA-4 results in an autoimmune phenotype similar to the one seen after CD4+ CD25+ Treg depletion [102] . One proposed mechanism involves the interaction of B7 (CD80/86) on APC or activated T cells with CTLA-4 constitutively expressed on Tregs, sending an inhibitory signal to the APC or T cell [103] (Figure 3 ). This theory is supported by the finding that suppression of T cells not expressing CD80/86 is reduced compared to the suppression of wildtype T cells in vitro [103] . There is contradictory evidence on this matter, however, as Tregs from CTLA-4-deficient mice have the same suppressive activity in vitro as those from normal mice [39, 102] . Furthermore, this contact-dependent mechanism does not appear to operate indirectly [104] .
Soluble factors: cytokine-driven suppression
The observation that suppression is prevented by a permeable membrane does not eliminate the possibility of soluble mediators working over a short distance. Furthermore, the finding that suppressors and their targets can co-exist for long periods of time without an increase in the rate of apoptosis in target cells suggests that direct killing through cytotoxicity is not the major mechanism of suppression in vivo [105, 106] . Suppression also appears to be reversible as separation of previously co-existing suppressor and target cells shows that CD4+ CD25-cells can proliferate and secrete IL-2 following antigenic stimulation when the Tregs are removed [105, 106] . In fact, if the effector T cells were committed to a certain lineage prior to suppression, that commitment is retained following the removal of suppressor cells [105] . These data argue that Tregs mediate reversible suppression through the release of soluble factors (Figure 3) .
Both IL-10 and TGF-β have been linked to suppression in vivo, although specific mechanisms have not been confirmed [98, 99, 107, 108] . The role for IL-10, for instance, is ambiguous; Tregs require secretion of this cytokine in order to suppress some autoimmune diseases such as colitis, while it is not required for suppression of others (e.g., autoimmune gastritis) [98, 105, [107] [108] [109] . The story in vivo is complicated by the fact that several classes of regulatory T cells exist in the periphery, all of which may utilize different mechanisms of suppression, and some of which do rely on soluble factors. It is possible that secretion of soluble factors also contributes to suppression by natural Tregs, although more conclusive evidence is required.
A passive mechanism of suppression: competition for IL-2
As mentioned above, IL-2-or IL-2R-deficient mice lack CD25+ Tregs and develop severe autoimmune diseases, which can be prevented by transferring CD4+ CD25+ regulatory T cells in vivo [79, 110] . This suggests that IL-2 plays a role in Treg maintenance and function [81, 84, 111] . Due to the importance of the growth factor IL-2, a passive mechanism has been proposed in which Tregs mediate sup- Immunological tolerance with Foxp3 914 npg pression by sequestering the IL-2 produced by non-regulatory T cells: IL-2 fuels Treg expansion and suppressive function, while effector T cells suffer in the absence of this essential growth factor [105, 112] (Figure 3 ).
There are likely multiple, redundant mechanisms of suppression by natural Tregs, which vary depending on the tissue and model of inflammation being studied. Different tissues have different microenvironments and concentrations of antigen to fuel suppressor activity in various ways. The mechanism of action may take place indirectly over a short distance by soluble mediators such as cytokines, or through direct cell contact of suppressors and either APC intermediates or the effector T-cell targets themselves. Regardless of the mechanism, suppression requires the ability of Tregs to localize with APC and ligand for priming by TCR stimulation, as well as the ability to migrate to inflamed tissues to find their targets [99, 113] . Overall, the degree of Treg-mediated suppression is dependent on the frequency of CD25+ CD4+ T cells, access to sufficient concentration of antigen presented by APC, and localization with effector T-cell targets. The cytokine environment required to support Treg growth, maintenance, and activation of suppressor function in the periphery at the time of antigen encounter is critical as well.
Induced Tregs and other regulatory populations
Thymic development is not the only means of generating regulatory T cells, and naturally occurring Tregs are not the only subset of T cells exhibiting suppressor function [114] . The focus of this review has been on the thymically derived class of naturally occurring suppressors, referred to as nTregs. However, T cells exhibiting regulatory function can develop in the periphery as well (Figure 1 ). Naïve CD4+ CD25-Foxp3-T cells in the periphery can be converted into Foxp3+ CD25+ CD4+ Tregs with suppressor function following TCR stimulation in the presence of low-dose peptide antigen or TGFβ [115] [116] [117] . These 'induced' or 'adaptive' Tregs mediate suppressor activity through secretion of TGFβ or IL-10 [115] . Interestingly, while TGFβ in the steady state fuels differentiation of induced Tregs which control autoimmunity in the periphery, the presence of TGFβ in combination with IL-6 following inflammation drives development of Th17 cells, which themselves induce autoimmune diseases [23] . This fine line in the differentiation of two counteractive T-cell subsets illustrates how precisely balanced the immune system must remain in order to generate the necessary response. Another regulatory subset, the antigen-specific 'Tr1' cells, can be generated by culturing CD4+ T cells with antigen in the presence of IL-10 [118] . As reviewed by Shevach, antigen-specific Tr1 cells can also be induced by in vivo in order to control the inflammatory response to infectious pathogens [114] . Notably, these cells do not express Foxp3. A mucosal type of Treg, designated as Th3 cells, can be induced by food antigens and play important roles in preventing food hypersensitivity [35] . These cells can be either Foxp3+ or Foxp3 [119] . They can also be induced to suppress autoimmune diseases following oral administration of the corresponding self-antigens. And if this were not enough to keep the autoreactive effectors at bay, data suggest that certain populations of CD8+ and CD4-CD8-double-negative regulatory T cells exist as well [114] .
Prospects
The suppressor T-cell field has come a long way since the 1980s, when it seemed that the scientific community had all but given up on the idea that a class of T cells with suppressor function could truly exist. In the past several decades researchers have made significant progress: from cloning suppressor cells, to identifying specific markers, delineating regulatory subtypes, and understanding their development, phenotype, peripheral maintenance, and function. Despite all of the advances in the field, much remains to be discovered. The contributions of Marson et al. and Zheng et al. in identifying Foxp3 target genes will certainly fuel interest in Foxp3-mediated gene expression and its role in regulatory T-cell development. Details of thymic lineage commitment, including the role of other transcription factors with cooperative or independent roles in gene regulation, are of interest. Accessory signaling molecules and the upstream genetic program directing expression of Foxp3 following TCR stimulation both in the thymus and in the periphery also remain unknown. A greater understanding of the precise delineations between subclasses of T cells that possess regulatory function is certainly in our future, as is the search for their exact mechanisms of suppression both in vitro and in vivo. With a renewed interest in the existence of this unique population of cells, in addition to their potential for treating autoimmunity and regulating the immune response to tumors or infectious pathogens, there is little doubt that the field will continue to answer these questions in the decades to come.
